Key result
An activation-based high throughput screen identified thiadiazine-containing compounds and pifithrin-μ as caspase-10 inhibitors that show preferential zymogen inhibition.
The study identifies new caspase-10 inhibitors and demonstrates the utility of an activation-based high throughput screening platform for state-specific protease inhibitors.
Answers are grounded in this paper and cite their sources.
No clinical role yet; leaves open caspase-10 as a druggable target pending human validation of zymogen-preferring inhibitors.
procaspase-10 inhibitors. Confirmatory studies identified a class of thiadiazine-containing compounds that undergo isomerization and oxidation to generate cysteine-reactive compounds with caspase-10 inhibitory activity. In parallel, mode-of-action studies revealed that pifithrin-μ (PFTμ), a reported TP53 inhibitor, also functions as a promiscuous caspase inhibitor. Both inhibitor classes showed preferential zymogen inhibition. Given the generalized utility of activation assays, we expect our screening platform to have widespread applications in identifying state-specific protease inhibitors.
No takes yet. Share an insight, caveat, or question.
Castellón et al. (2025) studied this question. Thiadiazine-containing compounds and pifithrin-μ was evaluated on Caspase-10 inhibitory activity. An activation-based high throughput screen identified thiadiazine-containing compounds and pifithrin-μ as caspase-10 inhibitors that show preferential zymogen inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: